Loading... Please wait...

Micatu Submits Application for 2013 Innovation Expo in Collaboration with the Smithsonian Institution and the United States Patent and Trademark Office

Posted

Painted Post, NY, April 4, 2013 — Micatu, Inc. provider of next generation optical based sensors, measurement and biomedical instruments, announced today that they have completed their application for the 2013 Innovation Expo in Collaboration with the Smithsonian Institution and the United States Patent and Trademark Office.

The Innovation Expo showcases technological advances made possible, in part, by the mission of the United States Patent and Trademark Office to protect and promote intellectual property. Featured patented technologies that have attained evident commercial success as well as influenced and demonstrated significant contributions to both technological advancement and the standard of living in the United States are considered. Inventions or products that qualify for Innovation Expo must have also established a new market or significantly reshaped an existing market.

Recently, Micatu was awarded a Phase 1 contract for the development of a “Low Cost Tissue Micro Array Instrument” (TMA), through the NIH/NCI. This invention is a simplified, low-cost tissue microarray instrument for use in clinical and research settings to help validate the immunohistochemical (IHC) assays for cancer diagnosis.  Tissue cores are inserted in a recipient paraffin block in a precisely spaced, array pattern. Sections from this block are cut using a microtome, mounted on a microscope slide and then analyzed by any method of standard histological analysis. Each microarray block can be cut into 100 – 500 sections, which can be subjected to immunohistochemistry and fluorescent in situ hybridization.

“Micatu was also awarded an exclusive license from NIH Office of Technology Transfer (OTT) for the design, production and commercialization of a bio-medical instrument that has the capability of reducing existing technology costs for similar instruments by a factor of 8X to 30X.”  In just under 7 months’ time, Micatu, working through the Ceramics Corridor Innovation Center (CCIC) was able to design, develop and begin manufacturing a viable low cost tissue microarray instrument for the histology and pathology marketplace 14 months ahead of schedule” stated Michael Oshetski, CEO of Micatu, Inc. “Micatu also has been invited to apply for Phase II funding and grant applications, well in advance of the standardized timelines for other companies competing in this space”.     

“The Ceramics Corridor Innovation Center (CCIC) has been a fantastic resource that allows for us to leverage the technical and business synergies they provide in a very cost effective manner,” stated Michael Jagielski, Micatu’s Chief Operating Officer. “Within the CCIC incubator, we have the access to world class facilities, subject matter expertise and plethora of business focused programs that create a significant differential advantage for our company to rapidly commercialize products”.

Micatu’s facility is centrally located in Upstate New York, next to the I-86 corridor and the Elmira regional airport (ELM).

About Micatu: Micatu innovates and pioneers advanced technologies that enable next generation optical based sensors, measurement and biomedical instruments. We drive first to market technologies that are highly accurate, highly precise, which enable our customers to achieve profitable and sustainable operations. Micatu's inventive culture, combined with practicality, had enabled next generation instruments within our key product lines while reducing costs for our customers.  For more information, please see us on the web at: www.micaarray.com & www.micatu.com.



Popular Brands

Recent Updates

Sign up to our newsletter


Connect with us: LinkedIn